Role of TP53 mutations in the origin and evolution of th leukaemia

Nature

518, 552-555

DOI: 10.1038/nature13968

Citation Report

#	Article	IF	Citations
1	Optimizing Cancer Genome Sequencing and Analysis. Cell Systems, 2015, 1, 210-223.	2.9	174
2	Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q). International Journal of Medical Sciences, 2015, 12, 719-726.	1.1	16
3	Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Reports in Hematology, 2015, 2015, 1-5.	0.3	2
4	Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. ELife, 2015, 4, e06907.	2.8	140
5	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology, 2015, 8, 45.	6.9	101
6	Evolved Cellular Mechanisms to Respond to Genotoxic Insults: Implications for Radiation-Induced Hematologic Malignancies. Radiation Research, 2015, 184, 341-351.	0.7	8
7	Update on recurrent genetic aberrations in acute myeloid leukemia. International Journal of Hematologic Oncology, 2015, 4, 179-190.	0.7	1
8	Exploring origins and evolution. Nature Reviews Cancer, 2015, 15, 68-69.	12.8	0
9	BRCA2-associated therapy-related acute myeloid leukemia. Medical Oncology, 2015, 32, 371.	1.2	3
10	How cell death shapes cancer. Cell Death and Disease, 2015, 6, e1675-e1675.	2.7	205
11	Evolutionary Determinants of Cancer. Cancer Discovery, 2015, 5, 806-820.	7.7	350
12	Back to 2D Culture for Ground State of Intestinal Stem Cells. Cell Stem Cell, 2015, 17, 5-7.	5.2	5
13	Aspp1: A Guardian of Hematopoietic Stem Cell Integrity. Cell Stem Cell, 2015, 17, 3-5.	5.2	5
14	Therapy-Related Myeloid Neoplasms. American Journal of Clinical Pathology, 2015, 144, 207-218.	0.4	25
15	Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing. Leukemia, 2015, 29, 1608-1611.	3.3	77
16	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1425-1430.	2.0	12
17	Distinguishing clonal evolution from so-called secondary acute myelogenous leukemia: Adhering to unifying concepts of the genetic basis of leukemogenesis. Blood Cells, Molecules, and Diseases, 2015, 55, 1-2.	0.6	3
18	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 2015, 126, 9-16.	0.6	1,493

#	Article	IF	Citations
19	Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 264-275.	3.3	48
20	A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. Current Hematologic Malignancy Reports, 2015, 10, 225-236.	1.2	2
21	Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma. Nature Communications, 2015, 6, 8477.	5.8	39
22	<scp>TP</scp>53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. British Journal of Haematology, 2015, 171, 91-99.	1.2	43
23	TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer Journal, 2015, 5, e331-e331.	2.8	130
24	DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. Clinical Chemistry, 2015, 61, 1354-1362.	1.5	9
25	Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing. Trends in Cancer, 2015, 1, 231-241.	3.8	25
26	Concepts and challenges in cancer risk prediction for the space radiation environment. Life Sciences in Space Research, 2015, 6, 92-103.	1.2	75
27	Preexisting TP53 mutation in therapy-related acute myeloid leukemia. Annals of Hematology, 2015, 94, 527-529.	0.8	27
28	Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Advances, 2016, 1, 193-204.	2.5	63
29	TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget, 2016, 7, 36266-36279.	0.8	47
30	Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells. Oncotarget, 2016, 7, 60575-60592.	0.8	40
31	Hallmarks of glioblastoma: a systematic review. ESMO Open, 2016, 1, e000144.	2.0	122
32	Personalized Cancer Risk Assessments for Space Radiation Exposures. Frontiers in Oncology, 2016, 6, 38.	1.3	10
33	Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PLoS ONE, 2016, 11, e0159189.	1.1	2
34	Therapy-related myeloid neoplasms. Current Opinion in Hematology, 2016, 23, 161-166.	1.2	17
35	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. EBioMedicine, 2016, 10, 117-123.	2.7	153
36	<scp>TP</scp>53 mutation in patients with highâ€risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2016, 172, 914-922.	1.2	74

#	Article	IF	Citations
37	Pharmacological activation of wild-type p53 in the therapy of leukemia. Experimental Hematology, 2016, 44, 791-798.	0.2	41
38	The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026153.	2.9	35
39	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). American Journal of Hematology, 2016, 91, 227-232.	2.0	46
40	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	0.9	32
41	Attenuated DNA damage repair delays therapy-related myeloid neoplasms in a mouse model. Cell Death and Disease, 2016, 7, e2401-e2401.	2.7	9
42	Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nature Communications, 2016, 7, 12484.	5.8	523
43	Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. Diagnostic Pathology, 2016, 11, 11.	0.9	77
44	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genetics, 2016, 209, 205-214.	0.2	6
45	An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases. Oncogene, 2016, 35, 5328-5336.	2.6	9
46	Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. Future Oncology, 2016, 12, 1565-1575.	1.1	10
47	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6005-6010.	3.3	135
48	Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood, 2016, 127, 29-41.	0.6	356
49	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	0.6	94
50	Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood, 2016, 128, e1-e9.	0.6	49
51	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1961-1967.	2.0	30
52	Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 175, 169-172.	1.2	12
53	Molecular Pathology. Surgical Pathology Clinics, 2016, 9, 475-488.	0.7	4
54	Critical Updates to the Leukemia Stem Cell Model. , 2016, , 101-119.		2

#	Article	IF	Citations
55	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	3.3	57
56	Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood, 2016, 127, 42-52.	0.6	234
57	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	2.0	200
58	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nature Communications, 2016, 7, 12609.	5.8	73
59	Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. Cancer Science, 2016, 107, 1484-1491.	1.7	9
60	Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nature Communications, 2016, 7, 12475.	5.8	95
61	Acute myeloid leukemia with TP53 germ line mutations. Blood, 2016, 128, 2270-2272.	0.6	39
62	Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia. Oncology Letters, 2016, 12, 262-268.	0.8	10
63	â€˜CHIPâ€™ping away at clonal hematopoiesis. Leukemia, 2016, 30, 1633-1635.	3.3	48
64	Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 89-95.	0.6	37
65	Genome Stability Requires p53. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026096.	2.9	101
66	Leveraging protein quaternary structure to identify oncogenic driver mutations. BMC Bioinformatics, 2016, 17, 137.	1.2	8
67	Somatic Mosaic Mutations inPPM1DandTP53in the Blood of Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 370.	3.4	88
68	Regain control of p53: Targeting leukemia stem cells by isoform-specificÂHDAC inhibition. Experimental Hematology, 2016, 44, 315-321.	0.2	22
69	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surgical Pathology Clinics, 2016, 9, 143-163.	0.7	14
70	Deja Visite. American Journal of Clinical Pathology, 2016, 145, 296-298.	0.4	1
71	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research, 2016, 9, 2-10.	0.7	130
72	The influence of subclonal resistance mutations on targeted cancer therapy. Nature Reviews Clinical Oncology, 2016, 13, 335-347.	12.5	185

#	Article	IF	Citations
73	Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia, 2016, 30, 243-247.	3.3	6
74	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	0.8	339
75	P53 deletion and NrasG12D cooperate for AML. Blood, 2017, 129, 271-273.	0.6	0
76	Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Cancer Genetics, 2017, 211, 5-8.	0.2	45
77	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood, 2017, 129, 1469-1479.	0.6	276
78	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncology, 2017, 3, 936.	3.4	90
79	Changing mutational and adaptive landscapes and the genesis of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 84-94.	3.3	27
80	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2127-2133.	0.6	20
81	Hypermutation signature reveals a slippage and realignment model of translesion synthesis by Rev3 polymerase in cisplatin-treated yeast. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2663-2668.	3.3	18
82	Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes. Haematologica, 2017, 102, e216-e218.	1.7	16
83	More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood, 2017, 129, 2584-2587.	0.6	51
84	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine, 2017, 376, 536-547.	13.9	586
85	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood, 2017, 129, 2587-2591.	0.6	44
86	A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 109-126.	3.3	37
87	Hematopoiesis Lineage Tree Uprooted: Every Cell Is a Rainbow. Developmental Cell, 2017, 41, 7-9.	3.1	8
88	Nicaraven, a Potential Radioprotective Agent, has Very Limited Effects on the Survival of Cancer Cells and the Growth of Established Tumors. Radiation Research, 2017, 187, 339.	0.7	7
89	Therapy-related myeloid neoplasms. Current Opinion in Hematology, 2017, 24, 152-158.	1.2	30
90	Characterization of TP53 mutations in clonal cytopenia of undetermined significance. American Journal of Hematology, 2017, 92, E175-E177.	2.0	4

#	Article	IF	Citations
91	Preleukemia: one name, many meanings. Leukemia, 2017, 31, 534-542.	3.3	51
92	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	5.1	296
93	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncology, The, 2017, 18, 112-121.	5.1	249
94	Predicting therapy-related myeloid neoplasmsâ€"and preventing them?. Lancet Oncology, The, 2017, 18, 11-13.	5.1	9
95	Cooperative genomic alteration network reveals molecular classification across 12 major cancer types. Nucleic Acids Research, 2017, 45, 567-582.	6.5	32
96	DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppression. Carcinogenesis, 2017, 38, 367-377.	1.3	39
97	Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. Haematologica, 2017, 102, 1549-1557.	1.7	28
98	PRKCH regulates hematopoietic stem cell function and predicts poor prognosis in acute myeloid leukemia. Experimental Hematology, 2017, 53, 43-47.	0.2	13
99	CHIP, ICUS, CCUS and other four-letter words. Leukemia, 2017, 31, 1869-1871.	3.3	71
100	Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. Experimental Hematology, 2017, 53, 48-58.	0.2	15
101	Myeloproliferative Neoplasms. New England Journal of Medicine, 2017, 376, 2168-2181.	13.9	274
102	Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood, 2017, 130, 699-712.	0.6	128
104	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	0.6	4,375
105	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017, 129, 667-679.	0.6	444
106	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica, 2017, 102, 719-727.	1.7	33
107	Therapy-related myelodysplastic syndromes, or are they?. Blood Reviews, 2017, 31, 119-128.	2.8	28
108	DNMT3A in Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030320.	2.9	135
109	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica, 2017, 102, 2030-2038.	1.7	26

#	Article	IF	Citations
110	Clonal evolution in leukemia. Nature Medicine, 2017, 23, 1135-1145.	15.2	93
111	MALT1 Inhibition Is Efficacious in Both NaÃ¯ve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. Cancer Research, 2017, 77, 7038-7048.	0.4	41
112	Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1765-1780.	0.9	109
113	Clonality in context: hematopoietic clones in their marrow environment. Blood, 2017, 130, 2363-2372.	0.6	74
114	RUNX1 Upregulation by Cytotoxic Drugs Promotes Apoptosis. Cancer Research, 2017, 77, 6818-6824.	0.4	8
115	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	12.8	270
116	Targeting apoptosis in acute myeloid leukaemia. British Journal of Cancer, 2017, 117, 1089-1098.	2.9	61
117	Characterization of <scp>TP</scp>53 mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. European Journal of Haematology, 2017, 99, 536-543.	1.1	20
118	Putting p53 in Context. Cell, 2017, 170, 1062-1078.	13.5	1,355
119	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	5.2	578
120	Myeloproliferative neoplasms: from origins to outcomes. Blood, 2017, 130, 2475-2483.	0.6	107
121	The genomic landscape of pediatric myelodysplastic syndromes. Nature Communications, 2017, 8, 1557.	5.8	143
122	The Spindle Assembly Checkpoint Is Required for Hematopoietic Progenitor Cell Engraftment. Stem Cell Reports, 2017, 9, 1359-1368.	2.3	10
123	First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease. Molecular and Translational Medicine, 2017, , 155-176.	0.4	1
125	Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. American Journal of Human Genetics, 2017, 101, 50-64.	2.6	210
126	Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. Haematologica, 2017, 102, 1502-1510.	1.7	41
127	Class I histone deacetylases regulate p53/NF-ÎºB crosstalk in cancer cells. Cellular Signalling, 2017, 29, 218-225.	1.7	41
128	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nature Reviews Cancer, 2017, 17, 5-19.	12.8	542

#	Article	IF	Citations
129	Clonal hematopoiesis. Seminars in Hematology, 2017, 54, 43-50.	1.8	100
130	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia, 2017, 31, 301-309.	3.3	61
131	Overexpression of <scp>TP</scp>53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia. British Journal of Haematology, 2017, 178, 810-812.	1.2	6
132	Molecular biomarkers in acute myeloid leukemia. Blood Reviews, 2017, 31, 63-76.	2.8	205
133	The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia, 2017, 31, 705-711.	3.3	158
134	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia, 2017, 31, 1286-1295.	3.3	44
135	Targeting acute myeloid leukemia with TP53-independent vosaroxin. Future Oncology, 2017, 13, 125-133.	1.1	5
136	Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Scientific Reports, 2017, 7, 16604.	1.6	29
137	Aging, hematopoiesis, and the myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2017, 2017, 73-78.	0.9	17
138	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 480-494.	1.8	9
139	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget, 2017, 8, 29887-29905.	0.8	9
140	Myeloproliferative neoplasms: from origins to outcomes. Hematology American Society of Hematology Education Program, 2017, 2017, 470-479.	0.9	29
141	Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Advances, 2017, 1, 1031-1036.	2.5	30
142	Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Advances, 2017, 1, 2572-2578.	2.5	35
143	A case of lenalidomide-dependent myelodysplastic syndrome. Blood Advances, 2017, 1, 1238-1242.	2.5	1
144	Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis. OncoTargets and Therapy, 2018, Volume 11, 163-173.	1.0	24
145	The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells. PLoS ONE, 2017, 12, e0168888.	1.1	39
146	Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Oncotarget, 2017, 8, 72621-72632.	0.8	51

#	Article	IF	Citations
147	Therapy-related myeloid neoplasms as a concerning complication in acute promyelocytic leukemia. Hematology Reports, 2017, 9, 7204.	0.3	4
148	Precancerous Clonal Expansion: A New Therapeutic Target?. Journal of Clinical Oncology, 2017, 35, 1503-1505.	0.8	0
149	La prÃ©sence dâ€™hÃ©matopoÃ¯Ã¨ses clonales de signification indÃ©terminÃ©es permet-elle de prÃ©dire la survenue dâ€™une hÃ©mopathie secondaire Ã un traitement pour cancer chez les patients de plus de 70 ansÃ?. Hematologie, 2017, 23, 20-21.	0.0	0
150	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2017, 35, 968-974.	0.8	117
151	Uncoding the genetic heterogeneity of myelodysplastic syndrome. Hematology American Society of Hematology Education Program, 2017, 2017, 447-452.	0.9	26
152	The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia. Experimental Cell Research, 2018, 365, 185-193.	1.2	17
153	Ups and downs of CHIP. Blood, 2018, 131, 1773-1774.	0.6	0
154	p53: emerging roles in stem cells, development and beyond. Development (Cambridge), 2018, 145, .	1.2	89
155	Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell, 2018, 22, 157-170.	5.2	345
156	How I treat myelodysplastic syndromes of childhood. Blood, 2018, 131, 1406-1414.	0.6	75
157	Myeloid Neoplasms Following Solid Organ Transplantation. American Journal of Clinical Pathology, 2018, 149, 55-66.	0.4	11
158	Bone Marrow Microâ€Environment in Normal and Deranged Hematopoiesis: Opportunities for Regenerative Medicine and Therapies. BioEssays, 2018, 40, 1700190.	1.2	17
159	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	5.8	150
160	A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia, 2018, 32, 1493-1499.	3.3	39
161	Somatic Mutations and Clonal Hematopoiesis. Circulation Research, 2018, 122, 523-532.	2.0	129
162	Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica, 2018, 103, e143-e146.	1.7	41
163	Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53. Leukemia, 2018, 32, 850-854.	3.3	26
164	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. Blood, 2018, 131, 1846-1857.	0.6	35

#	Article	IF	Citations
165	Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association?. Haematologica, 2018, 103, 751-752.	1.7	6
166	New Insights from Studies of Clonal Hematopoiesis. Clinical Cancer Research, 2018, 24, 4633-4642.	3.2	76
167	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 1189-1199.	13.9	605
168	Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. , 2018, , 197-236.		0
169	Diagnosis and Treatment of Acute Myeloid Leukemia in Children. , 2018, , 359-374.		0
170	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biology and Therapy, 2018, 19, 664-668.	1.5	4
171	Mutation analysis of therapy-related myeloid neoplasms. Cancer Genetics, 2018, 222-223, 38-45.	0.2	11
172	Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease. Leukemia and Lymphoma, 2018, 59, 241-244.	0.6	16
173	Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia, 2018, 32, 450-461.	3.3	54
174	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2021-2039.	0.6	8
175	Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood, 2018, 131, 408-416.	0.6	91
176	Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. Journal of Pediatric Hematology/Oncology, 2018, 40, e23-e28.	0.3	3
177	Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia, 2018, 32, 952-959.	3.3	30
178	Age-related clonal hematopoiesis. Blood, 2018, 131, 496-504.	0.6	215
179	The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 339-341.	0.4	2
180	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 555-573.	1.8	71
181	Noxa: Role in Cancer Pathogenesis and Treatment. Current Cancer Drug Targets, 2018, 18, 914-928.	0.8	34
182	Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics. JCO Precision Oncology, 2018, 2, 1-6.	1.5	0

#	Article	IF	Citations
183	Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation. Current Opinion in Hematology, 2018, 25, 441-445.	1.2	6
184	Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype. PLoS ONE, 2018, 13, e0209800.	1.1	2
185	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer, 2018, 124, 4601-4609.	2.0	8
186	Significance of Cytogenetics in Leukemia Diagnostics. Current Genetic Medicine Reports, 2018, 6, 165-175.	1.9	1
187	Therapy-related myeloid neoplasms: clinical perspectives. OncoTargets and Therapy, 2018, Volume 11, 5909-5915.	1.0	12
188	Patterns of mutations in TP53 mutated AML. Best Practice and Research in Clinical Haematology, 2018, 31, 379-383.	0.7	43
189	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
190	The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence. Gynecologic Oncology, 2018, 151, 187-189.	0.6	4
191	Myelodysplastic syndromes in children. Current Opinion in Oncology, 2018, 30, 402-408.	1.1	19
192	TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome. Leukemia Research, 2018, 74, 97-104.	0.4	9
193	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell, 2018, 23, 700-713.e6.	5.2	272
194	MPN: Next Questionsâ€“Understanding Fibrotic and Leukemic Transformation of MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S43-S44.	0.2	0
195	Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. Circulation Journal, 2018, 83, 2-11.	0.7	42
196	A monocentric retrospective study of 138 therapy-related myeloid neoplasms. Annals of Hematology, 2018, 97, 2319-2324.	0.8	9
197	Cell-lineage levelâ€“targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. Blood Advances, 2018, 2, 2513-2521.	2.5	10
198	Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 461-466.	2.3	19
199	Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 47.	2.8	107
200	Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature. Leukemia Research Reports, 2018, 9, 65-71.	0.2	7

#	Article	IF	Citations
201	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood, 2018, 132, 1095-1105.	0.6	160
202	Acute myeloid leukaemia. Lancet, The, 2018, 392, 593-606.	6.3	512
203	Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. Leukemia Research, 2018, 72, 86-91.	0.4	7
204	Therapy-Related Acute Myelogenous Leukemia. , 2018, , 465-482.		0
205	Clonal Hematopoiesis in Aging. Current Stem Cell Reports, 2018, 4, 209-219.	0.7	18
206	Incidence and survival of therapy related myeloid neoplasm in United States. Leukemia Research, 2018, 71, 95-99.	0.4	24
207	Conventional and Molecular Cytogenomic Basis of Hematologic Malignancies. , 2018, , 774-848.		0
208	Pathobiology of Acute Myeloid Leukemia. , 2018, , 913-923.		1
210	Acute Myeloid Leukemia. , 2018, , 429-466.e5.		6
211	Diagnosis and Prognosis: Molecular. Hematologic Malignancies, 2018, , 15-37.	0.2	0
212	Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404.	13.7	617
213	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. , 2018, , 563-563.		0
214	Therapy-related acute myeloid leukemia developing 14â€¯years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. Experimental and Molecular Pathology, 2018, 105, 139-143.	0.9	2
215	How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resistance Updates, 2018, 38, 27-43.	6.5	91
216	Management of postâ€transplant lymphoproliferative disorders. British Journal of Haematology, 2018, 182, 330-343.	1.2	63
217	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1406-1414.	2.0	44
218	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia, 2018, 32, 2066-2069.	3.3	4
219	Additional germline findings from a tumor profiling program. BMC Medical Genomics, 2018, 11, 65.	0.7	16

#	Article	IF	Citations
220	Rare Event Detection Using Error-corrected DNA and RNA Sequencing. Journal of Visualized Experiments, 2018, , .	0.2	9
221	Cytopenias: Reactive and Neoplastic. , 2018, , 17-79.		1
222	Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. Stem Cells, 2018, 36, 1287-1294.	1.4	60
223	Genetic and epigenetic determinants of AML pathogenesis. Seminars in Hematology, 2019, 56, 84-89.	1.8	65
225	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	6.0	265
226	The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes and Cancer, 2019, 58, 875-888.	1.5	79
227	Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development, 2019, 4, 263-274.	0.4	2
228	Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Modern Pathology, 2019, 32, 1712-1726.	2.9	33
229	Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes. Expert Review of Hematology, 2019, 12, 821-831.	1.0	6
230	Analysis of TP53 gene in uterine myomas: No mutations but P72R polymorphism is associated with myoma development. Journal of Obstetrics and Gynaecology Research, 2019, 45, 2088-2094.	0.6	1
231	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. , 0, , .		0
232	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. Blood Reviews, 2019, 37, 100587.	2.8	23
234	Clonal hematopoiesis in human aging and disease. Science, 2019, 366, .	6.0	590
236	Long Non-coding RNAs in Myeloid Malignancies. Frontiers in Oncology, 2019, 9, 1048.	1.3	35
237	Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leukemia Research, 2019, 86, 106227.	0.4	2
238	The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Annals of Hematology, 2019, 98, 541-559.	0.8	34
239	Genetics of MDS. Blood, 2019, 133, 1049-1059.	0.6	241
240	The mesenchymal niche in MDS. Blood, 2019, 133, 1031-1038.	0.6	54

#	Article	IF	Citations
241	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert Review of Clinical Pharmacology, 2019, 12, 197-218.	1.3	15
242	Premature Aging in Young Cancer Survivors. Journal of the National Cancer Institute, 2019, 111, 226-232.	3.0	61
243	Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 177-185.	0.7	15
244	Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. Cancer Genetics, 2019, 237, 82-89.	0.2	7
245	Emerging patterns in clonal haematopoiesis. Journal of Clinical Pathology, 2019, 72, 453-459.	1.0	2
246	The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. American Journal of Hematology, 2019, 94, 913-920.	2.0	31
247	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplantation, 2019, 54, 1987-1994.	1.3	25
248	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. Cancer Discovery, 2019, 9, 962-979.	7.7	58
249	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 2019, 33, 2842-2853.	3.3	43
250	Current status and new treatment approaches in TP53 mutated AML. Best Practice and Research in Clinical Haematology, 2019, 32, 134-144.	0.7	63
251	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 400-410.	1.8	58
252	Evolutionary trajectory of leukemic clones and its clinical implications. Haematologica, 2019, 104, 872-880.	1.7	17
253	Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. Blood, 2019, 134, 186-198.	0.6	43
254	Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	1.0	16
255	Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica, 2019, 104, 2410-2417.	1.7	73
256	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 2019, 10, 2031.	5.8	87
257	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genetics, 2019, 235-236, 31-38.	0.2	23
258	Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 1550-1559.	2.0	51

#	Article	IF	Citations
259	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2019, 138, 6-13.	2.0	16
260	Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers, 2019, 11, 260.	1.7	28
261	Myeloid malignancies after treatment for solid tumours. Best Practice and Research in Clinical Haematology, 2019, 32, 40-46.	0.7	8
262	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. Blood, 2019, 133, 2718-2724.	0.6	31
263	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer. JAMA Cardiology, 2019, 4, 380.	3.0	42
264	Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterationsâ€"Possible Therapeutic Efficacy of Cabozantinib. International Journal of Molecular Sciences, 2019, 20, 1230.	1.8	5
265	Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology, 2019, 37, 7-11.	0.8	60
266	Clonal hematopoiesis and preleukemiaâ€"Genetics, biology, and clinical implications. Genes Chromosomes and Cancer, 2019, 58, 828-838.	1.5	18
267	Rapidly progressive therapy-related myeloid neoplasm in a patient treated for Burkitt lymphoma: A case report. Human Pathology: Case Reports, 2019, 16, 100285.	0.2	1
268	A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes. Leukemia, 2019, 33, 2481-2494.	3.3	4
269	Rational â€œError Eliminationâ€•Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. Journal of Molecular Diagnostics, 2019, 21, 471-482.	1.2	1
270	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. Best Practice and Research in Clinical Haematology, 2019, 32, 104-113.	0.7	5
271	Clonal approaches to understanding the impact of mutations on hematologic disease development. Blood, 2019, 133, 1436-1445.	0.6	14
272	TP53 and therapy-related myeloid neoplasms. Best Practice and Research in Clinical Haematology, 2019, 32, 98-103.	0.7	9
273	Stem cell damage after chemotherapy- can we do better?. Best Practice and Research in Clinical Haematology, 2019, 32, 31-39.	0.7	6
274	Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. Best Practice and Research in Clinical Haematology, 2019, 32, 3-12.	0.7	12
275	Myeloid disorders after autoimmune disease. Best Practice and Research in Clinical Haematology, 2019, 32, 74-88.	0.7	19
276	Clonal Hematopoiesis and therapy related MDS/AML. Best Practice and Research in Clinical Haematology, 2019, 32, 13-23.	0.7	17

#	Article	IF	Citations
277	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances, 2019, 3, 3962-3967.	2.5	12
278	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	2.5	34
279	Molecular Genetics in Myelodysplasia Outcomes Prognostication. Advances in Molecular Pathology, 2019, 2, 35-43.	0.2	0
280	p53 involvement in clonal hematopoiesis of indeterminate potential. Current Opinion in Hematology, 2019, 26, 235-240.	1.2	21
281	Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nature Communications, 2019, 10, 5649.	5.8	77
282	Genome Sequencing during a Patientâ€™s Journey through Cancer. New England Journal of Medicine, 2019, 381, 2145-2156.	13.9	50
283	Clinical implications of molecular markers in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 20-35.	1.1	44
284	Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle. Future Oncology, 2019, 15, 65-79.	1.1	4
285	Comparative outcomes of myeloablative and reducedâ€intensity conditioning allogeneic hematopoietic cell transplantation for therapyâ€related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. American Journal of Hematology, 2019, 94, 431-438.	2.0	16
286	Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment. Haematologica, 2019, 104, 789-796.	1.7	25
287	Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors. International Journal of Radiation Oncology Biology Physics, 2019, 103, 52-61.	0.4	10
288	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84
289	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1204-1213.	0.4	75
290	Minimal Residual Disease Testing. , 2019, , .		1
291	Anemia in the Young and Old. , 2019, , .		0
292	Exome analysis of treatmentâ€related <scp>AML</scp> after <scp>APL</scp> suggests secondary evolution. British Journal of Haematology, 2019, 185, 984-987.	1.2	1
293	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer Journal, 2019, 9, 7.	2.8	64
294	Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica, 2019, 104, 516-523.	1.7	65

#	Article	IF	Citations
295	Lowâ€level <scp>TP</scp>53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 184, 657-659.	1.2	2
296	Oscillatory Dynamics of p53-Mdm2 Circuit in Response to DNA Damage Caused by Ionizing Radiation. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2020, 17, 1703-1713.	1.9	2
297	Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Haematologica, 2020, 105, 358-365.	1.7	5
298	A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2020, 22, 60-71.	1.2	11
299	Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk. Environmental and Molecular Mutagenesis, 2020, 61, 152-175.	0.9	13
300	Potential screening assays for individual radiation sensitivity and susceptibility and their current validation state. International Journal of Radiation Biology, 2020, 96, 280-296.	1.0	29
301	Mitochondrial dysfunction and oxidative stress in bone marrow stromal cells induced by daunorubicin leads to DNA damage in hematopoietic cells. Free Radical Biology and Medicine, 2020, 146, 211-221.	1.3	12
302	A substantial proportion of apparently heterozygousTP53pathogenic variants detected with a nextâ€generation sequencing hereditary panâ€cancer panel are acquired somatically. Human Mutation, 2020, 41, 203-211.	1.1	19
303	Genomics of therapy-related myeloid neoplasms. Haematologica, 2020, 105, e98-e101.	1.7	23
305	Treatment Strategies for Therapy-related Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 147-155.	0.2	10
306	Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. Journal of Molecular Diagnostics, 2020, 22, 396-404.	1.2	17
307	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer, 2020, 20, 5.	1.1	16
308	Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematology,the, 2020, 7, e73-e81.	2.2	45
309	How to address second and therapyâ€related acute myelogenous leukaemia. British Journal of Haematology, 2020, 188, 116-128.	1.2	18
310	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 1027-1033.	1.5	20
311	Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Advances, 2020, 4, 4887-4897.	2.5	40
312	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 2020, 38, 3883-3894.	0.8	168
313	Clonal hematopoiesis: Molecular basis and clinical relevance. Leukemia Research, 2020, 98, 106457.	0.4	2

#	Article	IF	Citations
314	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. HemaSphere, 2020, 4, .	1.2	2
315	Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating Factor. Cytogenetic and Genome Research, 2020, 160, 255-263.	0.6	3
316	Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia. BMC Cancer, 2020, 20, 1081.	1.1	2
317	Clonal hematopoiesis in the inherited bone marrow failure syndromes. Blood, 2020, 136, 1615-1622.	0.6	26
318	Clonal hematopoiesis and risk for hematologic malignancy. Blood, 2020, 136, 1599-1605.	0.6	35
319	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 1399-1420.	2.0	119
320	Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones. Blood, 2020, 136, 1590-1598.	0.6	67
321	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
322	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
323	Dnmt3a-null hematopoietic stem and progenitor cells expand after busulfan treatment. Experimental Hematology, 2020, 91, 39-45.e2.	0.2	6
324	The risk of developing acute non-lymphocytic leukemia in women with breast cancer. Translational Cancer Research, 2020, 9, 2701-2709.	0.4	2
325	Experiences with next-generation sequencing in relapsed acute myeloid leukemia: a patient case series. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020068.	0.5	2
326	Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers, 2020, 12, 2277.	1.7	83
327	Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting. Scientific Reports, 2020, 10, 14403.	1.6	6
328	Cytotoxic Therapyâ€“Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 32-47.	2.6	16
329	Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 10-12.	2.6	1
330	Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing. Science Advances, 2020, 6, .	4.7	6
331	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	2.5	21

#	Article	IF	Citations
332	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689.	2.5	105
333	Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia and Lymphoma, 2020, 61, 2180-2190.	0.6	24
334	TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. International Journal of Molecular Sciences, 2020, 21, 3432.	1.8	25
335	Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology, 2020, 8, 249.	1.8	29
336	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. Blood Reviews, 2020, 42, 100712.	2.8	16
337	Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood, 2020, 135, 2000-2004.	0.6	26
338	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	5.8	98
339	AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. Experimental Hematology, 2020, 87, 13-19.	0.2	12
340	Implications of Clonal Hematopoiesis for Precision Oncology. JCO Precision Oncology, 2020, 4, 639-646.	1.5	16
341	The role of host environment in cancer evolution. Evolutionary Applications, 2020, 13, 1756-1770.	1.5	15
342	Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15182-15192.	3.3	93
343	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. Journal of Hematology and Oncology, 2020, 13, 72.	6.9	123
344	Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia. Journal of Clinical Medicine, 2020, 9, 802.	1.0	28
345	The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science, 2020, 367, 1449-1454.	6.0	294
346	Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring. BMC Medical Genomics, 2020, 13, 32.	0.7	14
347	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Genes, 2020, 11, 749.	1.0	30
348	Clonal hematopoiesis in myeloma: root of all maladies!. Blood, 2020, 135, 2330-2331.	0.6	2
350	Clonal hematopoiesis in cancer. Experimental Hematology, 2020, 83, 105-112.	0.2	24

#	Article	IF	Citations
351	Clonal Hematopoiesis: AÂNewÂStepÂLinking Inflammation toÂHeartÂFailure. JACC Basic To Translational Science, 2020, 5, 196-207.	1.9	33
352	Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia. EBioMedicine, 2020, 52, 102664.	2.7	15
353	Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms. Advances in Cell and Gene Therapy, 2020, 3, e78.	0.6	1
354	The Clinical Management of Clonal Hematopoiesis. Hematology/Oncology Clinics of North America, 2020, 34, 357-367.	0.9	42
355	Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. Current Opinion in Hematology, 2020, 27, 66-75.	1.2	6
356	Secondary Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America, 2020, 34, 449-463.	0.9	17
357	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine, 2020, 12, .	5.8	41
358	Second malignancies in multiple myeloma; emerging patterns and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101144.	0.7	27
359	Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Leukemia, 2020, 34, 1816-1827.	3.3	13
360	60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations. Experimental Hematology, 2020, 83, 2-11.	0.2	24
361	TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model. Annals of Hematology, 2020, 99, 653-655.	0.8	5
362	Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children. Leukemia, 2020, 34, 3382-3387.	3.3	35
363	Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma. Haematologica, 2020, 105, e337-e339.	1.7	7
364	Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Literature Review. Oncology and Therapy, 2020, 8, 45-57.	1.0	9
365	Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. Blood, 2020, 135, 1185-1188.	0.6	29
366	FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood, 2020, 135, 1472-1483.	0.6	52
367	Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy. JAMA Oncology, 2020, 6, 1086.	3.4	30
368	Clinical potential of introducing nextâ€generation sequencing in patients at relapse of acute myeloid leukemia. Hematological Oncology, 2020, 38, 425-431.	0.8	8

#	Article	IF	Citations
369	Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. Blood, 2020, 135, 1161-1170.	0.6	30
370	Stem cell donors should not be screened for clonal hematopoiesis. Blood Advances, 2020, 4, 789-792.	2.5	27
371	Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms postâ€“autologous stem cell transplantation. Blood Advances, 2020, 4, 885-892.	2.5	33
372	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034975.	2.9	8
373	Acute myeloid leukemia arising from polycythemia vera underwent reversion to chronic phase of myeloproliferative neoplasm status post chemotherapy: Biclonal myeloid neoplasms with genomic evidence of a common early hematopoietic progenitor. Hematological Oncology, 2021, 39, 254-257.	0.8	1
374	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplantation, 2021, 56, 334-346.	1.3	9
375	Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. Blood Reviews, 2021, 47, 100760.	2.8	7
376	Preleukemic and leukemic evolution at the stem cell level. Blood, 2021, 137, 1013-1018.	0.6	9
377	Therapeutic Vulnerabilities of Transcription Factors in AML. Molecular Cancer Therapeutics, 2021, 20, 229-237.	1.9	8
378	Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. Blood, 2021, 137, 1260-1263.	0.6	5
379	Distinctive Flow Cytometric and Mutational Profile of Acute Myeloid Leukemia With t(8;16)(p11;p13) Translocation. American Journal of Clinical Pathology, 2022, 157, 701-708.	0.4	5
380	Acute Myeloid Leukemia. , 2021, , 275-304.		0
381	TP53 mutated myeloid malignancies and their treatment strategy. Journal of Hematopoietic Cell Transplantation, 2021, 10, 7-15.	0.1	0
382	The Molecular Pathobiology of Malignant Process and Molecular Diagnostic Testing for Cancer. , 2021, , 3-21.		1
383	Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy. Cell Reports, 2021, 34, 108751.	2.9	13
384	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. Biology, 2021, 10, 128.	1.3	5
385	Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. Expert Review of Hematology, 2021, 14, 199-210.	1.0	5
386	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985.	5.8	31

#	Article	IF	Citations
387	Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis. Leukemia, 2021, 35, 2407-2411.	3.3	3
388	TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?. Frontiers in Oncology, 2020, 10, 610820.	1.3	38
389	Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101249.	0.7	9
390	Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. Current Hematologic Malignancy Reports, 2021, 16, 192-206.	1.2	11
392	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918.	1.3	10
393	Whatâ€™s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood, 2021, 138, 749-757.	0.6	23
394	Myelodysplastic syndromes and overlap syndromes. Blood Research, 2021, 56, S51-S64.	0.5	4
395	Genotoxic Bystander Signals from Irradiated Human Mesenchymal Stromal Cells Mainly Localize in the 10â€“100 kDa Fraction of Conditioned Medium. Cells, 2021, 10, 827.	1.8	3
396	Genetic therapies for the first molecular disease. Journal of Clinical Investigation, 2021, 131, .	3.9	17
397	Type of prior genotoxic insult determines the genomic characteristics of therapyâ€related myeloid neoplasms. American Journal of Hematology, 2021, 96, E223-E225.	2.0	2
398	Chromosomal Instability in Acute Myeloid Leukemia. Cancers, 2021, 13, 2655.	1.7	14
399	Somatic Mutations in â€œBenignâ€•Disease. New England Journal of Medicine, 2021, 384, 2039-2052.	13.9	111
401	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood, 2021, 137, 2992-2997.	0.6	19
402	Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma. Cancer Research, 2021, 81, 3777-3790.	0.4	10
403	Loss of a 7q gene,CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood, 2021, 138, 790-805.	0.6	13
404	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. European Journal of Haematology, 2021, 107, 275-282.	1.1	8
405	The Interpretation of Sequence Variants in Myeloid Neoplasms. American Journal of Clinical Pathology, 2021, 156, 728-748.	0.4	1
406	A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. Cancer Discovery, 2021, 11, 3126-3141.	7.7	17

#	Article	IF	Citations
407	Mutagenic Consequences of Sublethal Cell Death Signaling. International Journal of Molecular Sciences, 2021, 22, 6144.	1.8	7
408	Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	2.0	40
409	Clonal hematopoiesis and bone marrow failure syndromes. Best Practice and Research in Clinical Haematology, 2021, 34, 101273.	0.7	6
410	Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease. Cardiovascular Research, 2022, 118, 1413-1432.	1.8	12
411	Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1481-1492.	1.2	1
412	TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight, 2021, 6, .	2.3	37
413	The beginning of a new therapeutic era in acute myeloid leukemia. EJHaem, 2021, 2, 823-833.	0.4	3
414	Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms. Acta Clinica Belgica, 2022, 77, 658-663.	0.5	1
415	Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clinical Chemistry, 2021, 67, 1062-1070.	1.5	0
416	Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics, 2021, 13, 1129-1143.	1.0	2
417	Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 841-851.	0.2	2
418	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer, 2021, 2, 819-834.	5.7	24
419	Clonal Hematopoiesis: From Mechanisms to Clinical Intervention. Cancer Discovery, 2021, 11, 2987-2997.	7.7	30
420	The evolution of hematopoietic cells under cancer therapy. Nature Communications, 2021, 12, 4803.	5.8	28
421	Emerging Role of Acquired Mutations and Clonal Hematopoiesis in Atherosclerosisâ€â€â€• Beyond Conventional Cardiovascular Risk Factors â€•. Circulation Journal, 2023, 87, 394-400.	0.7	4
422	Clonal hematopoiesis and myeloid malignancies. Current Opinion in Hematology, 2021, Publish Ahead of Print, 347-355.	1.2	4
424	Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. HemaSphere, 2021, 5, e632.	1.2	10
425	Update on Clonal Hematopoiesis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S32-S33.	0.2	1

#	Article	IF	Citations
426	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances, 2021, 5, 4140-4148.	2.5	6
427	Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplantation, 2021, 56, 2997-3007.	1.3	4
428	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treatment Reviews, 2021, 99, 102255.	3.4	25
429	The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice. Circulation Research, 2021, 129, 684-698.	2.0	42
430	Transition and identification of pathological states in p53 dynamics for therapeutic intervention. Scientific Reports, 2021, 11, 2349.	1.6	1
431	Epidemiology and Etiology of AML. Hematologic Malignancies, 2021, , 1-22.	0.2	3
432	Genomic Landscape and Clonal Evolution of AML. Hematologic Malignancies, 2021, , 103-118.	0.2	0
433	Secondary AML. Hematologic Malignancies, 2021, , 71-101.	0.2	0
434	Myelodysplastic Syndrome. Molecular Pathology Library, 2018, , 83-98.	0.1	1
435	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resistance Updates, 2020, 52, 100703.	6.5	25
441	Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance. Cancer Research, 2019, 79, 5799-5811.	0.4	24
442	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 2018, 3, .	2.3	48
443	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	0.9	34
444	Clonal Hematopoiesis: The Seeds of Leukemia or Innocuous Bystander?. , 2016, 13, .		2
445	Tumour Cell Heterogeneity. F1000Research, 2016, 5, 238.	0.8	91
447	Stem cells, aging and cancers. Aging, 2015, 7, 457-458.	1.4	4
448	Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies. Oncotarget, 2016, 7, 58586-58594.	0.8	9
449	Targeting prohibitins induces apoptosis in acute myeloid leukemia cells. Oncotarget, 2016, 7, 64987-65000.	0.8	19

#	Article	IF	Citations
450	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	0.8	9
451	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	0.8	22
452	p53 pathway dysfunction in AML: beyond TP53 mutations. Oncotarget, 2017, 8, 108288-108289.	0.8	6
453	Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair. Oncotarget, 2019, 10, 4679-4690.	0.8	5
454	Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget, 2016, 7, 8105-8118.	0.8	19
455	The Evolving AML Genomic Landscape: Therapeutic Implications. Current Cancer Drug Targets, 2020, 20, 532-544.	0.8	8
456	Myelodysplastic syndromes: moving towards personalized management. Haematologica, 2020, 105, 1765-1779.	1.7	52
457	Panelâ€based nextâ€generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings. Biomedical Reports, 2020, 13, 1-1.	0.9	5
458	Advances in Polycythemia Vera and Lessons for Acute Leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101330.	0.7	4
459	p53 in Acute Myeloid Leukemia-Still a significant other. Leukemia and Lymphoma, 2021, , 1-3.	0.6	0
460	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	3.4	44
461	Advances in acute myeloid leukemia. BMJ, The, 2021, 375, n2026.	3.0	177
462	Success Stories and Challenges Ahead in Hematopoietic Stem Cell Gene Therapy: Hemoglobinopathies as Disease Models. Human Gene Therapy, 2021, 32, 1120-1137.	1.4	3
463	Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Riskâ€"Clues to a Mechanistic Connection?. JAMA Oncology, 2021, 7, 1763.	3.4	0
464	TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. International Journal of Molecular Sciences, 2021, 22, 10782.	1.8	25
466	Therapy-Related Myeloid Neoplasms. , 2016, , 5-134-5-137.		0
470	Role of Cell Cycle Control, Checkpoints and DNA Repair Mechanisms in Stem Cells and Changes with Aging and Cancerogenesis. , 2018, , 1-17.		0
471	LeucÃ©mies liÃ©es Ã des traitements anticancÃ©reux : spÃ©cificitÃ©s, difficultÃ©s et perspectives. Psycho-oncologie, 2017, 11, 203-209.	0.0	0

#	Article	IF	Citations
472	VII. Pathological Mechanism and Treatment of Therapy-related AML. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1316-1323.	0.0	0
474	Neoplastische BildungsstÃ¶rungen der HÃmatopoiese mit Ausreifungsverlust. , 2019, , 115-139.		0
475	Clonal Hematopoiesis and Cytopenias in theÂElderly. , 2019, , 195-212.		0
476	ML-DS: A Unique Condition for Measurable Residual Disease Detection. , 2019, , 139-157.		0
477	A Case of Therapy-related Acute Myeloid Leukemia Following Treatment with 5-Fluorouracil. Cureus, 2018, 10, e3769.	0.2	2
479	Precision Medicine in Clonal Hematopoiesis: New Data on Risk for Transformation. , 2020, 17, .		0
481	TP53 in Myelodysplastic Syndromes. Cancers, 2021, 13, 5392.	1.7	8
482	The microbiome of a shell mound: ancient anthropogenic waste as a source of Streptomyces degrading recalcitrant polysaccharides. World Journal of Microbiology and Biotechnology, 2021, 37, 210.	1.7	1
483	Molecular Genetics and Cell Biology for Hematopathology. , 2020, , 15-34.		0
484	Identification of Malignant Cell Populations Years Before Development of Treatment-related Leukemia in Patients With Myeloma. , 2020, 17, .		0
485	Molecular Landscape of MDS. , 2020, , 73-90.		0
486	Role of Cell Cycle Control, Checkpoints, and DNA Repair Mechanisms in Stem Cells and Changes with Aging and Cancerogenesis. , 2020, , 37-53.		0
488	The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time. Frontiers in Genetics, 2021, 12, 760039.	1.1	12
489	Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	1.5	7
493	Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology, 2016, 30, 330, 333.	0.4	0
496	Allogeneic hematopoietic stem cell transplantation overcomes the poor prognosis in MLL-rearranged solid tumor therapy related-acute myeloid leukemia. American Journal of Cancer Research, 2021, 11, 1683-1696.	1.4	0
497	Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. Cancer Research, 2022, 82, 199-209.	0.4	11
498	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	3.2	4

#	Article	IF	Citations
499	Diagnosis and treatment of therapy-related acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2022, 171, 103607.	2.0	19
500	Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 460-465.	1.3	4
501	TP53 mutation defines a unique subgroup within complex karyotype deÂnovo and therapy-related MDS/AML. Blood Advances, 2022, 6, 2847-2853.	2.5	87
502	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology, 2022, 49, 19-26.	0.8	5
503	Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology, 2022, 6, e2100309.	1.5	15
504	TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood Advances, 2022, 6, 3201-3206.	2.5	8
505	What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?. Cancer Journal (Sudbury, Mass), 2022, 28, 51-61.	1.0	5
506	Endothelial cells: major players in acute myeloid leukaemia. Blood Reviews, 2022, 54, 100932.	2.8	9
507	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2022, 139, 2347-2354.	0.6	131
508	What Clonal Hematopoiesis Can Teach Us About MDS. Frontiers in Oncology, 2022, 12, 794021.	1.3	1
509	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. American Journal of Blood Research, 2021, 11, 472-497.	0.6	2
510	Pseudo-mutant P53 is a unique phenotype of <i>DNMT3A</i>-mutated pre-leukemia. Haematologica, 2022, 107, 2548-2561.	1.7	6
511	The hematopoietic saga of clonality in sickle cell disease. Journal of Clinical Investigation, 2022, 132, .	3.9	4
512	TP53 Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia. Diagnostics, 2022, 12, 724.	1.3	1
513	Clonal haematopoiesis as a risk factor for therapyâ€related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemoâ€(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	1.2	7
514	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function. Cell Stem Cell, 2022, 29, 577-592.e8.	5.2	13
515	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	0.8	0
516	The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Annals of Hematology, 2022, 101, 1227-1237.	0.8	5

#	Article	IF	Citations
517	A review of the mutagenic potential of Nâ€ethylâ€Nâ€nitrosourea (ENU) to induce hematological malignancies. Journal of Biochemical and Molecular Toxicology, 2022, 36, e23067.	1.4	4
518	Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies. Journal of the National Cancer Institute, 2021, , .	3.0	0
519	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.	1.7	19
520	Peripheral blood parameter abnormalities precede therapyâ€related myeloid neoplasms after autologous transplantation for lymphoma. Cancer, 2022, 128, 1392-1401.	2.0	3
521	Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis. Modern Pathology, 2021, , .	2.9	1
523	The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. Hemato, 2021, 2, 748-763.	0.2	2
524	Therapyâ€‘related acute myeloid leukemia: A case series. Oncology Letters, 2022, 23, 171.	0.8	0
525	Monocytosis and Multiple Myeloma: treatment-related acute leukaemia?. Surgical and Experimental Pathology, 2022, 5, .	0.2	1
526	Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. OncoTargets and Therapy, 2022, Volume 15, 423-436.	1.0	14
527	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduction and Targeted Therapy, 2022, 7, 101.	7.1	15
529	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies. Cancer Letters, 2022, 538, 215691.	3.2	4
535	The dual role of autophagy in acute myeloid leukemia. Journal of Hematology and Oncology, 2022, 15, 51.	6.9	23
536	Ageing and cancer: a research gap to fill. Molecular Oncology, 2022, 16, 3220-3237.	2.1	7
537	The translational challenges of precision oncology. Cancer Cell, 2022, 40, 458-478.	7.7	38
538	Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood, 2022, 140, 1753-1763.	0.6	56
539	DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022030.	0.5	2
540	Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. Thrombosis Research, 2022, 213, S107-S112.	0.8	4
541	Clonal hematopoiesis: Mutation-specific adaptation to environmental change. Cell Stem Cell, 2022, 29, 882-904.	5.2	34

#	Article	IF	Citations
542	The longitudinal dynamics and natural history of clonal haematopoiesis. Nature, 2022, 606, 335-342.	13.7	136
543	Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. Blood Reviews, 2022, 56, 100986.	2.8	6
544	A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. Pathology and Oncology Research, 0, 28, .	0.9	7
545	Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells, 2022, 11, 2107.	1.8	7
546	Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms. Cancer Discovery, 0, , OF1-OF14.	7.7	5
547	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140, 1345-1377.	0.6	805
548	Hematopoyesis Clonal de Potencial Indeterminado (HCPI): mÃ¡s allÃ¡ de un modelo de campo de cancerizaciÃ³n. Revista Colombiana De CancerologÃa, 2021, 25, 210-221.	0.0	0
550	Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. Life, 2022, 12, 1135.	1.1	6
551	CHIPing away the progression potential of CHIP: A new reality in the making. Blood Reviews, 2023, 58, 101001.	2.8	6
553	Lesions learned from therapy-related acute myeloid leukemia. Haematologica, 0, , .	1.7	0
554	Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica, 2023, 108, 1015-1025.	1.7	13
555	EXABS-100-AML Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S3-S5.	0.2	0
556	Optimal treatment strategy of cancers with intratumor heterogeneity. Mathematical Biosciences and Engineering, 2022, 19, 13337-13373.	1.0	2
557	Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism. Blood, 2022, 140, 2514-2518.	0.6	13
558	CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022069.	0.5	1
559	Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia. International Journal of Hematology, 2022, 116, 902-910.	0.7	0
561	International expert group collaboration for developing an adverse outcome pathway for radiation induced leukemia. International Journal of Radiation Biology, 0, , 1-14.	1.0	2
563	Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiological Reviews, 2023, 103, 649-716.	13.1	21

#	Article	IF	Citations
564	Myeloid neoplasms on poly (ADP-ribose) polymerase inhibitor therapy. International Journal of Molecular and Immuno Oncology, 0, 7, 98-101.	0.0	1
566	TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discovery, 2022, 12, 2516-2529.	7.7	45
567	Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study. Blood Advances, 0, , .	2.5	0
568	Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Advances, 2023, 7, 236-245.	2.5	8
570	TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs. Leukemia and Lymphoma, 2023, 64, 540-550.	0.6	1
571	Clonal hematopoiesis and bone marrow inflammation. Translational Research, 2023, 255, 159-170.	2.2	3
572	Factors associated with clonal hematopoiesis and interaction with marrow environment. Journal of Bone and Mineral Metabolism, 0, , .	1.3	0
573	Haploidentical haematopoietic stem cell transplantation for TP53â€mutated acute myeloid leukaemia. British Journal of Haematology, 0, , .	1.2	0
574	TP53 Mutant Acute Myeloid Leukemia: The Immune and Metabolic Perspective. Hemato, 2022, 3, 742-757.	0.2	0
576	Inherited cancer predisposing mutations in patients with therapyâ€related myeloid neoplasms. British Journal of Haematology, 2023, 200, 489-493.	1.2	1
577	An RPS19-edited model for Diamond-Blackfan anemia reveals TP53-dependent impairment of hematopoietic stem cell activity. JCI Insight, 0, , .	2.3	4
578	Clonal Hematopoiesis and Its Impact on Human Health. Annual Review of Medicine, 2023, 74, 249-260.	5.0	18
579	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. Biomedicines, 2022, 10, 3008.	1.4	0
580	Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood, 2023, 141, 1846-1857.	0.6	15
581	Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review. Biomedicines, 2022, 10, 3201.	1.4	2
582	Identification of a signature based on nonâ€apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia. British Journal of Haematology, 0, , .	1.2	1
583	CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. Clinical Cancer Research, 2023, 29, 1403-1411.	3.2	9
584	Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. American Journal of Hematology, 2023, 98, 481-492.	2.0	11

#	Article	IF	Citations
585	Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from PreleukemicTP53-Mutant Clonal Hematopoiesis. Blood Cancer Discovery, 2023, 4, 134-149.	2.6	4
586	â€œLosing the Brakesâ€â€”Suppressed Inhibitors Triggering Uncontrolled Wnt/ÃŸ-Catenin Signaling May Provide a Potential Therapeutic Target in Elderly Acute Myeloid Leukemia. Current Issues in Molecular Biology, 2023, 45, 604-613.	1.0	0
588	Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17â€‰Years after Allogeneic Hematopoietic Stem Cell Transplantation. Case Reports in Hematology, 2022, 2022, 1-3.	0.3	1
589	Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precision Oncology, 2023, , .	1.5	3
590	Causes of Clonal Hematopoiesis: a Review. Current Oncology Reports, 2023, 25, 211-220.	1.8	1
591	Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-transplant Follow-Up: The Role of Next-Generation Sequencing. Biomedicines, 2023, 11, 359.	1.4	0
593	TP53 mutation variant allele frequency of â‰¥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 2023, 13, .	2.8	5
594	Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research, 2023, 129, 107076.	0.4	2
595	Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms. Leukemia Research, 2023, 126, 107020.	0.4	0
596	<scp>TP53</scp> signal pathway confers potential therapy target in acute myeloid leukemia. European Journal of Haematology, 2023, 110, 480-489.	1.1	0
597	The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica, 2023, 108, 308-320.	1.7	22
598	Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers. JAMA Network Open, 2023, 6, e2254221.	2.8	1
599	Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS. Blood Advances, 2023, 7, 2952-2956.	2.5	7
600	TP53 in AML and MDS: The new (old) kid on the block. Blood Reviews, 2023, 60, 101055.	2.8	1
601	Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea. Human Genomics, 2023, 17, .	1.4	1
603	Progress toward Better Treatment of Therapy-Related AML. Cancers, 2023, 15, 1658.	1.7	1
604	How I treat refractory/relapsed diffuse large Bâ€cell lymphomas with <scp>CD19</scp>â€directed <scp>chimeric antigen receptor</scp> T cells. British Journal of Haematology, 2023, 201, 396-410.	1.2	3
605	Patterns of mosaicism for sequence and copy-number variants discovered through clinical deep sequencing of disease-related genes in one million individuals. American Journal of Human Genetics, 2023, 110, 551-564.	2.6	3

#	Article	IF	Citations
606	Therapy-related MDS dissected based on primary disease and treatmentâ€"a nationwide perspective. Leukemia, 2023, 37, 1103-1112.	3.3	1
607	Identifying prognostic gene panels in acute myeloid leukemia. Expert Review of Hematology, 2023, 16, 277-287.	1.0	1
608	Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia, 2023, 37, 957-963.	3.3	2
609	Updates in molecular genetics of therapy-related myeloid neoplasms. Seminars in Diagnostic Pathology, 2023, , .	1.0	0
610	Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. Journal of the National Cancer Institute, 2023, 115, 981-988.	3.0	3
611	TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Biomedicines, 2023, 11, 1152.	1.4	2
612	The origins and functional effects of postzygotic mutations throughout the human life span. Science, 2023, 380, .	6.0	6
613	Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. Expert Review of Hematology, 2023, 16, 317-323.	1.0	1
614	Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies. Experimental Hematology, 2023, 122, 10-18.	0.2	1
617	Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients. , 2024, , 263-277.		0
637	Evolutionary genomic analysis for ALL. Nature Cancer, 2023, 4, 1058-1059.	5.7	0
638	Evolutionary determinants of curability in cancer. Nature Ecology and Evolution, 0, , .	3.4	1
643	Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly. Cell Death Discovery, 2023, 9, .	2.0	0
644	Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy. Nature Cancer, 2023, 4, 1095-1101.	5.7	2
646	Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications. Genome Instability & Disease, 2023, 4, 227-238.	0.5	0
655	Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. , 2023, , 119-128.		0
656	Therapy-Related MDS/AML and the Role of Environmental Factors. , 2023, , 409-420.		0
657	TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches. Annals of Hematology, 0, , .	0.8	2

#	Article	IF	Citations
669	Childhood Myelodysplastic Syndrome. , 2023, , 198-206.		0
670	15 years after a giant leap for cancer genomics. Nature, 2023, 623, 920-921.	13.7	0
672	Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nature Reviews Clinical Oncology, 2024, 21, 106-120.	12.5	2